Phaseline

Targets › POLD4

POLD4 (DNA polymerase delta subunit 4): drug programs, companies and trials

10 programs from 10 companies in 43 trials: 28 Phase 2, 13 Phase 1, 2 Phase 3; Oncology, Neurology, Hematology; next expected readout Dec 2026.

As a component of the tetrameric DNA polymerase delta complex (Pol-delta4), plays a role in high fidelity genome replication and repair. Within this complex, increases the rate of DNA synthesis and decreases fidelity by regulating POLD1 polymerase and proofreading 3' to 5' exonuclease activity. (UniProt, Q9HCU8)

Open in Phaseline: the race on POLD4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jiangsu Healthy Life Innovation Medical TechnologyGemcitabine hydrochloride
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 3Locally Advanced Pancreatic Cancer; Clear Cell Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Ovarian Brenner Tumor …Dec 2026
Memorial Sloan Kettering Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2AMLDec 2026
Dana-Farber Cancer InstituteClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell HistiocytosisDec 2026
M.D. Anderson Cancer CenterClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Recurrent Acute Lymphoblastic LeukemiaAug 2027
City of Hope Medical Centerclofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Adult Acute Lymphoblastic Leukemia in RemissionAug 2027
West China Second University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Langerhans Cell Histiocytosis (LCH)Jun 2028
Nantes University HospitalClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 2Acute Myeloid Leukemia in RemissionSep 2028
Princess Maxima Center for Pediatric OncologyClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Relapsed Pediatric AMLDec 2026
Ekaterina LaukhtinaClofarabine
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1Advanced Urothelial CarcinomaNov 2028
Beijing Immunochina Medical Science & TechnologyFludarabine Phosphate (IM19)
Ribonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) inhibitor
RRM1, RRM2B, RRM2, POLA1, POLD4Phase 1NHL; B-cell Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Refractory Idiopathic Aplastic Anemia …Jun 2035

Conditions

Acute Myeloid Leukemia in Remission (2) Acute Myeloid Leukaemia (AML) (2) Cancer (2) Metastatic Pancreatic Adenocarcinoma (2) Recurrent Acute Lymphoblastic Leukemia (1) Langerhans Cell Histiocytosis (1) NHL (1) B-cell Acute Lymphoblastic Leukemia (1) Myelodysplastic Syndromes (1) Refractory Idiopathic Aplastic Anemia (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1)

Modalities

small molecule (6), mixed (2), other (1), protein or peptide (1)

Companies

M.D. Anderson Cancer Center (1) Dana-Farber Cancer Institute (1) Nantes University Hospital (1) Beijing Immunochina Medical Science & Technology (1) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Jiangsu Healthy Life Innovation Medical Technology (1) Ekaterina Laukhtina (1) West China Second University Hospital (1) Princess Maxima Center for Pediatric Oncology (1)

Related targets

RRM1 (10) RRM2B (10) RRM2 (10) POLA1 (10)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.